在全球医药行业持续变革的背景下,2025年上半年各大制药企业的财务表现不仅反映了各自战略执行的有效性,也揭示了行业发展的整体趋势。本文通过对诺华、诺和诺德、阿斯利康、百济神州及赛诺菲五家代表性企业2025年上半年财报的系统梳理,全面剖析当前全球医药产业的竞争格局。数据显示,创新药已成为药企业绩增长的核心引擎,而国际化能力则成为企业分化的关键因素。与此同时,以ADC、GLP-1类药物为代表的新技术...
Source Link在全球医药行业持续变革的背景下,2025年上半年各大制药企业的财务表现不仅反映了各自战略执行的有效性,也揭示了行业发展的整体趋势。本文通过对诺华、诺和诺德、阿斯利康、百济神州及赛诺菲五家代表性企业2025年上半年财报的系统梳理,全面剖析当前全球医药产业的竞争格局。数据显示,创新药已成为药企业绩增长的核心引擎,而国际化能力则成为企业分化的关键因素。与此同时,以ADC、GLP-1类药物为代表的新技术...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.